Market Cap
$216.7M
PLX
Protalix BioTherapeutics, Inc.
$2.69 ▲ +0.56%
Prev close $2.68Market cap$216.7M
ConsensusStrong Buy
12-mo target$11.00 (+308.2%)
▲ Bullish
Analyst conviction 8/10
11 New Institutional Positions5 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on PLX right now — valuation, ownership and activity at a glance.
Cap Size
Micro Cap
Analyst Consensus
Strong Buy (80%)
Inst. Holders
50 funds
Inst. Value
$30.8M
Inst. Activity
11 buys / 5 sells
Social Sentiment
50° Neutral
SEC Reports
1
Price chart 30d +4.1%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 8, 2026 other
Protalix BioTherapeutics to Participate in Upcoming September 2026 Investor Conferences
CARMIEL, Israel, Sept. 8, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX),
Sep 3, 2026 Insider
Boudes Pol F was granted 8,500 shares
Director
Sep 3, 2026 Insider
Boudes Pol F was granted 17,000 shares
Director
Sep 3, 2026 Insider
Aug 12, 2026 SEC Bashan Dror was granted 160,000 shares
PRESIDENT AND CEO
Protalix BioTherapeutics reported Q2 2026 revenue of $19.9M, up 27% YoY, and net income of $3.8M ($0.05 EPS), compared t
8-K — Impact 5/10
Jun 30, 2026 Inst.
DIMENSIONAL FUND ADVISORS LP — ADD
493,424 shares ($1.1M)
Jun 30, 2026 Inst.
GOLDMAN SACHS GROUP INC — ADD
475,922 shares ($1.1M)
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
80% rate it Buy or better · 5 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 9, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 1 | 3 | 1 | 0 | 0 | 80% | |
| Aug 1, 2026 | 1 | 3 | 1 | 0 | 0 | 80% | |
| Jul 1, 2026 | 1 | 3 | 1 | 0 | 0 | 80% | |
| Jun 1, 2026 | 1 | 3 | 1 | 0 | 0 | 80% | |
| May 1, 2026 | 1 | 3 | 1 | 0 | 0 | 80% | |
| Apr 1, 2026 | 1 | 3 | 1 | 0 | 0 | 80% | |
| Mar 1, 2026 | 1 | 3 | 1 | 0 | 0 | 80% | |
| Feb 1, 2026 | 1 | 3 | 1 | 0 | 0 | 80% |
Price targets
Where 2 covering analysts think PLX trades over the next 12 months.
$11.00 +308.2% upside Strong Buy
Current$2.70 Low$10.00 Median$11.00 High$12.00 2 analysts
$10.00$12.00
Analyst rating None as of Oct 2, 2026
Social media sentiment
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
50°
Neutral
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
1 SEC filing reports analyzed · 0 bullish, 0 bearish, 1 mixed, 0 neutral · avg impact 5.0/10.
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 8, 2026
other
Protalix BioTherapeutics to Participate in Upcoming September 2026 Investor Conferences
CARMIEL, Israel, Sept. 8, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discove
Aug 14, 2026
short_volume
Short Volume: PLX — 61.8% short (0.3M / 0.5M)
Short: 318,669 | Exempt: 49,771 | TRF Vol: 515,610 | Short Ratio: 61.8% | Off-exchange volume (dark pool + OTC)
Aug 12, 2026
earnings_calendar
PLX Q2 2026 Earnings Scheduled — 2026-08-12
Jul 31, 2026
short_volume
Short Volume: PLX — 55.1% short (0.3M / 0.5M)
Short: 283,287 | Exempt: 2,501 | TRF Vol: 514,537 | Short Ratio: 55.1% | Off-exchange volume (dark pool + OTC)
May 13, 2026
earnings_calendar
PLX Q1 2026 Earnings Scheduled — 2026-05-13
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.02 | $-0.05–$0.01 | -166.7% | -100.0% | — | $0.0B | 2 |
| Next Q | $-0.01 | $-0.04–$0.01 | 78.6% | -50.0% | — | $0.0B | 2 |
| Current FY | $0.24 | $0.19–$0.29 | 400.0% | +23.1% | 1↑ 0↓ | $0.1B | 2 |
| Next FY | $0.05 | $-0.01–$0.11 | -79.2% | +0.0% | — | $0.1B | 2 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.020 | — |
| 7d ago | $-0.050 | +0.030 |
| 30d ago | $-0.010 | -0.010 |
| 60d ago | $-0.010 | -0.010 |
| 90d ago | $-0.010 | -0.010 |
Institutional ownership
Which big funds own PLX (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $30.8M total value (13,208,275 shares) as of 2026-Q2. Top holders: BlackRock,, RENAISSANCE, STATE. Net buying activity: 11 institutions added/increased vs 5 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 4,046,650 | $9.4M | 30.6% | — |
| RENAISSANCE TECHNOLOGIES LLC | 1,096,000 | $2.6M | 8.3% | — |
| STATE STREET CORP | 983,582 | $2.3M | 7.4% | ADD +66.2% |
| GEODE CAPITAL MANAGEMENT, LLC | 979,995 | $2.3M | 7.4% | — |
| NORTHERN TRUST CORP | 922,340 | $2.1M | 7.0% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 510,639 | $1.2M | 3.9% | — |
| DIMENSIONAL FUND ADVISORS LP | 493,424 | $1.1M | 3.7% | ADD +66.2% |
| GOLDMAN SACHS GROUP INC | 475,922 | $1.1M | 3.6% | ADD +89.4% |
| MARSHALL WACE, LLP | 452,757 | $1.1M | 3.4% | — |
| CITADEL ADVISORS LLC | 334,227 | $778.7K | 2.5% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| DIMENSIONAL FUND ADVISORS LP | ADD | 296,843 | 493,424 | +66.2% | $1.1M |
| GOLDMAN SACHS GROUP INC | ADD | 251,345 | 475,922 | +89.4% | $1.1M |
| LAZARD ASSET MANAGEMENT LLC | ADD | 86,617 | 165,561 | +91.1% | $385.8K |
| UBS Group AG | TRIM | 265,535 | 138,646 | -47.8% | $323.0K |
| JPMORGAN CHASE & CO | DOUBLED | 31,685 | 132,991 | +319.7% | $312.5K |
| WELLS FARGO & COMPANY/MN | DOUBLED | 26,522 | 67,549 | +154.7% | $157.4K |
| BANK OF AMERICA CORP /DE/ | TRIM | 79,079 | 51,896 | -34.4% | $120.9K |
| MORGAN STANLEY | NEAR_EXIT | 301,793 | 51,676 | -82.9% | $120.4K |
| CITIGROUP INC | DOUBLED | 2,958 | 34,689 | +1072.7% | $80.8K |
| Russell Investments Group, Ltd. | DOUBLED | 12,250 | 24,765 | +102.2% | $57.7K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
9 insiders, 18 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 3, 2026 | Boudes Pol F | Director | AWARD | 8,500 | — | — |
| Sep 3, 2026 | Boudes Pol F | Director | AWARD | 17,000 | — | — |
| Sep 3, 2026 | Bashan Dror | PRESIDENT AND CEO | AWARD | 160,000 | — | — |
| Sep 3, 2026 | Bashan Dror | PRESIDENT AND CEO | AWARD | 320,000 | — | — |
| Sep 3, 2026 | Elze Christian | Director | AWARD | 8,500 | — | — |
| Sep 3, 2026 | Elze Christian | Director | AWARD | 17,000 | — | — |
| Sep 3, 2026 | Naos Yaron | Sr. VP & COO | AWARD | 56,000 | — | — |
| Sep 3, 2026 | Ben Zvi Shmuel | Director | AWARD | 8,500 | — | — |
| Sep 3, 2026 | Ben Zvi Shmuel | Director | AWARD | 17,000 | — | — |
| Sep 3, 2026 | Melincoff Gwen A | Director | AWARD | 8,500 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for PLX.
Shares short
2,877,740
Settlement Sep 15, 2026
Change vs prior
-9.1%
Semi-monthly cycle
Days to cover
3.8
At avg daily volume
Of shares outstanding
≈3.6%
Estimate — not % of float
All PLX filing & press-release reports (1)
- 8-K reportAug 12, 2026